EBC-46
EBC-46 triggers a precisely ordered immune cascade — neutrophil infiltration within hours, macrophage cleanup within days, and adaptive T-cell memory that may prevent recurrence.
EBC-46
The EMA's PRIME programme offers accelerated assessment and early dialogue for promising cancer therapies. Here is what that pathway could mean for tigilanol tiglate.
EBC-46
Some of the most striking verified reports come from people facing stage 4 cancer diagnoses who began taking blushwood berry extract. These accounts are anecdotal — but they are also scientifically coherent.
EBC-46
Tigilanol tiglate gets all the scientific attention, but it is one compound within a chemically complex plant. The unmapped phytochemistry of Fontainea picrosperma may hold compounds we have not yet imagined.
EBC-46
The biomarkers chosen for EBC-46 trials are not arbitrary — they reflect the current scientific understanding of how tigilanol tiglate kills tumours. Here's what researchers are measuring and why it matters.
EBC-46
EBC-46 doesn't force its way into cells — it speaks their language. By mimicking diacylglycerol, the compound activates PKC with a precision that synthetic drugs rarely achieve. Here's the molecular story.
EBC-46
Before a drug achieves full approval, compassionate use and expanded access programmes can provide a legal pathway for patients who have no other options. Here's how they apply to tigilanol tiglate.
EBC-46
Supplement manufacturers have developed EBC-46 dosing protocols based on formulation research and real-world feedback. Here's what the data suggests about when and how to take it.
EBC-46
When a doctor looks up blushwood extract after seeing unexplained improvements in a patient's blood work, something remarkable is happening — and the scientific community should be paying attention.
EBC-46
EBC-46 belongs to the diterpene ester class — a family of plant compounds with extraordinary biological potency. Understanding this chemical context reveals why the Blushwood berry has captivated researchers.
EBC-46
Not every cancer patient qualifies for EBC-46 clinical trials. Tumour accessibility, prior treatment history, and lesion characteristics all determine eligibility — here is what the inclusion criteria reveal.
EBC-46
EBC-46 destroys the blood vessels feeding a tumour within hours of injection — cutting off oxygen and nutrients while leaving surrounding healthy vasculature intact. Here is the biology behind this precision.